| Literature DB >> 29847548 |
Shoji Kawashima1, Yoshino Ueki1,2, Takashi Kato3, Kengo Ito3, Noriyuki Matsukawa1.
Abstract
BACKGROUND: Striatal dopamine is functionally important for the acquisition of motor skills. However, it remains controversial as to whether intrinsic processing of motor learning is impaired in patients with Parkinson's disease (PD), and if yes, whether the impairment is associated with altered striatal dopamine release. Additionally, most neuro-imaging studies of patients with PD have focused on motor sequence learning. In contrast, skill acquisition, specifically, the reconstruction of muscle control of isolated movements, has barely been studied.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29847548 PMCID: PMC5976194 DOI: 10.1371/journal.pone.0196661
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Experimental protocol.
The upper panel shows the overview of experimental protocol. In the initial skill-training condition (Day 1), subjects performed one session of motor practice inside the scanner (session 1: 60 movements), and then completed three further sessions (sessions 2–4: 240 movements) while undergoing PET scanning. In the acquired condition (Day 2), 2 weeks later, subjects performed four blocks of a pre-practice task (block 1: 60 movements, blocks 2–4: 120 movements) 3 h before the PET scan, and then performed the motor task again in a manner identical to the initial skill-training condition (session 1: 60 movements, sessions 2–4: 240 movements). The lower-right panel illustrates data collection during PET scanning. The injection of RAC was performed into the subjects’ peripheral vein on their right forearm by an expert radiologist of the nuclear medicine. The computational motor task was performed on the subjects’ left hand by a neurologist. Subjects practiced rapid contraction of their left thumb to the beat of a metronome every 3 s, and learned how to accelerate their left thumb appropriately. They were then asked to perform the metronome-paced movement as quickly as possible, with the aid of visual feedback. The lower-left panel shows a sample image of RAC-BP and MRI T1. The RAC-BP indicated radioactivity concentration of the dopamine receptor. (A) RAC-BP image which was calculated using PMOD software (PMOD Technologies, Zurich, Switzerland). (B) Coronal and axial view of the co-registered RAC-BP image by using SPM5 software (Department of Imaging Neuroscience; freely available at http://www.fil.ion.ucl.ac.uk/spm). (C) The MRI T1 image for the registration with PET images.
Clinical characteristics of the patients with Parkinson’s disease.
| Age (years) | Duration (years) | HY stage | UPDRS motor | Laterality | LEDD (mg) | |
|---|---|---|---|---|---|---|
| Case- 1 (female) | 67 | 2 | 1 | 8 | Left | 201 |
| Case 2 (female) | 68 | 5 | 2 | 7 | Left | 125 |
| Case 3 (male) | 62 | 3 | 2 | 9 | Right | 100 |
| Case 4 (female) | 61 | 1 | 1 | 4 | Right | 380 |
| Case 5 (male) | 61 | 4 | 1 | 9 | Left | 220 |
| Case 6 (male) | 65 | 7 | 2 | 12 | Right | 150 |
| Case 7 (male) | 78 | 2 | 2 | 12 | Left | 300 |
| Case 8 (male) | 65 | 8 | 2 | 22 | Right | 702 |
| Mean ± SD | 65.9 ± 5.6 | 4 ± 2.5 | 1.6 ± 0.5 | 10.3 ± 5.4 | 272 ± 197 |
Duration: Disease duration from onset, HY stage: Hoehn and Yahr stage, UPDRS motor: motor sections of united PD rating scale, LEDD: l-dopa equivalent daily dose. Calculation of LEDD for each patient was based on the theoretical equivalence to l-dopa as follows: l-dopa dose + l-dopa dose × 1/3 [if on entacapone + bromocriptine (mg) × 10 + cabergoline or pramipexole (mg) × 67 + ropinirole (mg) × 20 + pergolide (mg) × 100 + apomorphine (mg) × 8].
Baseline characteristics between healthy subjects and patients with Parkinson’s disease.
| Healthy subjects | Parkinson’s disease patients | ||
|---|---|---|---|
| Gender | 5 males, 3 females | 5 males, 3 females | N.S. |
| Age | 68.7 ± 2.8 | 65.9 ± 5.6 | N.S. |
| MMSE | 28.2 ± 1.1 | 28.8 ± 0.6 | N.S. |
| TMT B-A | 57.5 ± 22.6 | 73.9 ± 58.1 | N.S. |
MMSE: mini mental scale examination, TMT B-A: Trail Making Test Part B-Part A (second)
N.S.: not significant
Fig 2Mean acceleration changes of healthy subjects (HS) and patients with Parkinson’s disease (PD).
(A) The graph shows the changes of mean acceleration of sessions 1–3 in patients with PD (left figure) and HS (right figure). (B) The graph shows the changes of the mean acceleration in session 1 between Day1 and Day2. Compared with the initial skill-training (Day 1), HS group showed significant increase of the mean acceleration in Day2. In PD group, the mean acceleration was not significantly changed in Day2.
11C-raclopride binding potential (RAC-BP) of the three ROI within the right striatum in healthy subjects (HS) and patients with Parkinson’s disease (PD).
| Healthy subjects | Parkinson’s disease | |||
|---|---|---|---|---|
| BP Day 1 | 2.11 ± 0.32 | 2.56 ± 0.61 | 0.08 | |
| BP Day 2 | 2.34 ± 0.29 | 2.67 ± 0.58 | N.S. | |
| BP Day 1 | 1.92 ± 0.47 | 1.67 ± 0.73 | N.S. | |
| BP Day 2 | 1.91 ± 0.31 | 1.54 ± 0.37 | <0.05 | |
| BP Day 1 | 2.17 ± 0.66 | 1.63 ± 0.56 | 0.09 | |
| BP Day 2 | 2.29 ± 0.55 | 1.69 ± 0.55 | <0.05 |
BP Day 1: 11C-raclopride binding potential on Day 1, BP Day 2: 11C-raclopride binding potential on Day 2, N.S.: not significant,
* statistically significant